FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947077325> ?p ?o ?g. }

• W2947077325 abstract "Background Prior to introducing pneumococcal conjugate vaccines (PCVs), Streptococcus pneumoniae was most commonly isolated from the middle ear fluid of children with acute otitis media (AOM). Reducing nasopharyngeal colonisation of this bacterium by PCVs may lead to a decline in AOM. The effects of PCVs deserve ongoing monitoring since studies from the post‐PCV era report a shift in causative otopathogens towards non‐vaccine serotypes and other bacteria. This updated Cochrane Review was first published in 2002 and updated in 2004, 2009, 2014, and 2019. Objectives To assess the effect of PCVs in preventing AOM in children up to 12 years of age. Search methods We searched CENTRAL, MEDLINE, Embase, CINAHL, LILACS, Web of Science, and two trials registers, ClinicalTrials.gov and WHO ICTRP, to 11 June 2020. Selection criteria Randomised controlled trials of PCV versus placebo or control vaccine. Data collection and analysis We used the standard methodological procedures expected by Cochrane. The primary outcomes were frequency of all‐cause AOM and adverse effects. Secondary outcomes included frequency of pneumococcal AOM and frequency of recurrent AOM (defined as three or more AOM episodes in six months or four or more in one year). We used GRADE to assess the certainty of the evidence. Main results We included 15 publications of 11 trials (60,733 children, range 74 to 37,868 per trial) of 7‐ to 11‐valent PCVs versus control vaccines (meningococcus type C vaccine in three trials, and hepatitis A or B vaccine in eight trials). We included one additional publication of a previously included trial for this 2020 update. We did not find any relevant trials with the newer 13‐valent PCV. Most studies were funded by pharmaceutical companies. Overall, risk of bias was low. In seven trials (59,415 children), PCVs were administered in early infancy, whilst four trials (1318 children) included children aged one year and over who were either healthy or had a history of respiratory illness. There was considerable clinical heterogeneity across studies, therefore we reported results from individual studies. PCV administered in early infancy PCV7 The licenced 7‐valent PCV with CRM197 as carrier protein (CRM197‐PCV7) was associated with a 6% (95% confidence interval (CI) −4% to 16%; 1 trial; 1662 children) and 6% (95% CI 4% to 9%; 1 trial; 37,868 children) relative risk reduction (RRR) in low‐risk infants (moderate‐certainty evidence), but was not associated with a reduction in all‐cause AOM in high‐risk infants (RRR −5%, 95% CI −25% to 12%). PCV7 with the outer membrane protein complex of Neisseria meningitidis serogroup B as carrier protein (OMPC‐PCV7) was not associated with a reduction in all‐cause AOM (RRR −1%, 95% CI −12% to 10%; 1 trial; 1666 children; low‐certainty evidence). CRM197‐PCV7 and OMPC‐PCV7 were associated with 20% (95% CI 7% to 31%) and 25% (95% CI 11% to 37%) RRR in pneumococcal AOM, respectively (2 trials; 3328 children; high‐certainty evidence), and CRM197‐PCV7 with 9% (95% CI −12% to 27%) and 10% (95% CI 7% to 13%) RRR in recurrent AOM (2 trials; 39,530 children; moderate‐certainty evidence). PHiD‐CV10/11 The effect of a licenced 10‐valent PCV conjugated to protein D, a surface lipoprotein of Haemophilus influenzae, (PHiD‐CV10) on all‐cause AOM in healthy infants varied from 6% (95% CI −6% to 17%; 1 trial; 5095 children) to 15% (95% CI −1% to 28%; 1 trial; 7359 children) RRR (low‐certainty evidence). PHiD‐CV11 was associated with 34% (95% CI 21% to 44%) RRR in all‐cause AOM (1 trial; 4968 children; moderate‐certainty evidence). PHiD‐CV10 and PHiD‐CV11 were associated with 53% (95% CI 16% to 74%) and 52% (95% CI 37% to 63%) RRR in pneumococcal AOM (2 trials; 12,327 children; high‐certainty evidence), and PHiD‐CV11 with 56% (95% CI −2% to 80%) RRR in recurrent AOM (1 trial; 4968 children; low‐certainty evidence). PCV administered at a later age PCV7 We found no evidence of a beneficial effect on all‐cause AOM of administering CRM197‐PCV7 in children aged 1 to 7 years with a history of respiratory illness or frequent AOM (2 trials; 457 children; moderate‐certainty evidence) and CRM197‐PCV7 combined with a trivalent influenza vaccine in children aged 18 to 72 months with a history of respiratory tract infections (1 trial; 597 children; moderate‐certainty evidence). CRM197‐PCV9 In 1 trial including 264 healthy daycare attendees aged 1 to 3 years, CRM197‐PCV9 was associated with 17% (95% CI −2% to 33%) RRR in parent‐reported all‐cause otitis media (very low‐certainty evidence). Adverse events Nine trials reported on adverse effects (77,389 children; high‐certainty evidence). Mild local reactions and fever were common in both groups, and occurred more frequently in PCV than in control vaccine groups: redness (< 2.5 cm): 5% to 20% versus 0% to 16%; swelling (< 2.5 cm): 5% to 12% versus 0% to 8%; and fever (< 39 °C): 15% to 44% versus 8% to 25%. More severe redness (> 2.5 cm), swelling (> 2.5 cm), and fever (> 39 °C) occurred less frequently (0% to 0.9%, 0.1% to 1.3%, and 0.4% to 2.5%, respectively) in children receiving PCV, and did not differ significantly between PCV and control vaccine groups. Pain or tenderness, or both, was reported more frequently in PCV than in control vaccine groups: 3% to 38% versus 0% to 8%. Serious adverse events judged to be causally related to vaccination were rare and did not differ significantly between groups, and no fatal serious adverse event judged causally related to vaccination was reported. Authors' conclusions Administration of the licenced CRM197‐PCV7 and PHiD‐CV10 during early infancy is associated with large relative risk reductions in pneumococcal AOM. However, the effects of these vaccines on all‐cause AOM is far more uncertain based on low‐ to moderate‐certainty evidence. We found no evidence of a beneficial effect on all‐cause AOM of administering PCVs in high‐risk infants, after early infancy, and in older children with a history of respiratory illness. Compared to control vaccines, PCVs were associated with an increase in mild local reactions (redness, swelling), fever, and pain and/or tenderness. There was no evidence of a difference in more severe local reactions, fever, or serious adverse events judged to be causally related to vaccination." @default.
• W2947077325 created "2019-06-07" @default.
• W2947077325 creator A5033079155 @default.
• W2947077325 creator A5036228795 @default.
• W2947077325 creator A5048500830 @default.
• W2947077325 creator A5057066875 @default.
• W2947077325 creator A5067266808 @default.
• W2947077325 creator A5071426349 @default.
• W2947077325 creator A5072067636 @default.
• W2947077325 date "2020-11-24" @default.
• W2947077325 modified "2023-10-01" @default.
• W2947077325 title "Pneumococcal conjugate vaccines for preventing acute otitis media in children" @default.
• W2947077325 cites W1177887580 @default.
• W2947077325 cites W1247968195 @default.
• W2947077325 cites W1845923557 @default.
• W2947077325 cites W1847505314 @default.
• W2947077325 cites W1912804674 @default.
• W2947077325 cites W1965859195 @default.
• W2947077325 cites W1967186914 @default.
• W2947077325 cites W1971003586 @default.
• W2947077325 cites W1975514483 @default.
• W2947077325 cites W1979454760 @default.
• W2947077325 cites W1980070970 @default.
• W2947077325 cites W1983346334 @default.
• W2947077325 cites W1985403003 @default.
• W2947077325 cites W1986705681 @default.
• W2947077325 cites W1989566543 @default.
• W2947077325 cites W1997080567 @default.
• W2947077325 cites W1999343936 @default.
• W2947077325 cites W2005730984 @default.
• W2947077325 cites W2007523601 @default.
• W2947077325 cites W2016143529 @default.
• W2947077325 cites W2016282998 @default.
• W2947077325 cites W2018947232 @default.
• W2947077325 cites W2023690749 @default.
• W2947077325 cites W2034867712 @default.
• W2947077325 cites W2038441646 @default.
• W2947077325 cites W2041643249 @default.
• W2947077325 cites W2045808776 @default.
• W2947077325 cites W2048547709 @default.
• W2947077325 cites W2051453885 @default.
• W2947077325 cites W2053322652 @default.
• W2947077325 cites W2059512533 @default.
• W2947077325 cites W2059608310 @default.
• W2947077325 cites W2068056929 @default.
• W2947077325 cites W2070398317 @default.
• W2947077325 cites W2071290196 @default.
• W2947077325 cites W2074074587 @default.
• W2947077325 cites W2077350726 @default.
• W2947077325 cites W2078137094 @default.
• W2947077325 cites W2083116246 @default.
• W2947077325 cites W2083249498 @default.
• W2947077325 cites W2086278702 @default.
• W2947077325 cites W2091066930 @default.
• W2947077325 cites W2094204413 @default.
• W2947077325 cites W2099409015 @default.
• W2947077325 cites W2102920015 @default.
• W2947077325 cites W2104139288 @default.
• W2947077325 cites W2105818435 @default.
• W2947077325 cites W2114673967 @default.
• W2947077325 cites W2115116421 @default.
• W2947077325 cites W2118832091 @default.
• W2947077325 cites W2121630139 @default.
• W2947077325 cites W2131732257 @default.
• W2947077325 cites W2138552522 @default.
• W2947077325 cites W2140353364 @default.
• W2947077325 cites W2141825831 @default.
• W2947077325 cites W2143570924 @default.
• W2947077325 cites W2145406400 @default.
• W2947077325 cites W2148212653 @default.
• W2947077325 cites W2150500774 @default.
• W2947077325 cites W2157244039 @default.
• W2947077325 cites W2162422751 @default.
• W2947077325 cites W2164754521 @default.
• W2947077325 cites W2165980650 @default.
• W2947077325 cites W2169729911 @default.
• W2947077325 cites W2170396769 @default.
• W2947077325 cites W2170759708 @default.
• W2947077325 cites W2171651817 @default.
• W2947077325 cites W2291228806 @default.
• W2947077325 cites W2307286688 @default.
• W2947077325 cites W2316733372 @default.
• W2947077325 cites W2317475805 @default.
• W2947077325 cites W2325285913 @default.
• W2947077325 cites W2337235121 @default.
• W2947077325 cites W2342686378 @default.
• W2947077325 cites W2411719747 @default.
• W2947077325 cites W2414608261 @default.
• W2947077325 cites W2518382899 @default.
• W2947077325 cites W2567362164 @default.
• W2947077325 cites W2591700839 @default.
• W2947077325 cites W2591947274 @default.
• W2947077325 cites W2604145379 @default.
• W2947077325 cites W2620584284 @default.
• W2947077325 cites W2734027913 @default.
• W2947077325 cites W2743818693 @default.
• W2947077325 cites W2779873194 @default.
• W2947077325 cites W2794433742 @default.
• W2947077325 cites W2794833470 @default.
• W2947077325 cites W2811334096 @default.

• next